Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization

Overview

Journal J Circ Biomark

Date 2017 Sep 23

PMID 28936239

Citations 70

Authors

Shannon L Werner

Ryon P Graf

Mark Landers

David T Valenta

Matthew Schroeder

Stephanie B Greene

Natalee Bales

Ryan Dittamore

Dena Marrinucci

Affiliations

Soon will be listed here.

Abstract

The Epic Platform was developed for the unbiased detection and molecular characterization of circulating tumour cells (CTCs). Here, we report assay performance data, including accuracy, linearity, specificity and intra/inter-assay precision of CTC enumeration in healthy donor (HD) blood samples spiked with varying concentrations of cancer cell line controls (CLCs). Additionally, we demonstrate clinical feasibility for CTC detection in a small cohort of metastatic castrate-resistant prostate cancer (mCRPC) patients. The Epic Platform demonstrated accuracy, linearity and sensitivity for the enumeration of all CLC concentrations tested. Furthermore, we established the precision between multiple operators and slide staining batches and assay specificity showing zero CTCs detected in 18 healthy donor samples. In a clinical feasibility study, at least one traditional CTC/mL (CK+, CD45-, and intact nuclei) was detected in 89 % of 44 mCRPC samples, whereas 100 % of samples had CTCs enumerated if additional CTC subpopulations (CK-/CD45- and CK+ apoptotic CTCs) were included in the analysis. In addition to presenting Epic Platform's performance with respect to CTC enumeration, we provide examples of its integrated downstream capabilities, including protein biomarker expression and downstream genomic analyses at single cell resolution.

Citing Articles

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.

Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B Nat Commun. 2025; 16(1):32.

PMID: 39746954 PMC: 11696112. DOI: 10.1038/s41467-024-55140-x.

A novel liquid biopsy assay for detection of (HER2) amplification in circulating tumor cells (CTCs).

Caro G, Lam E, Bourdon D, Blankfard M, Dharajiya N, Slade M J Circ Biomark. 2024; 13:27-35.

PMID: 39377016 PMC: 11456801. DOI: 10.33393/jcb.2024.3046.

Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection.

Bae S, Kamalanathan K, Galeano-Garces C, Konety B, Antonarakis E, Parthasarathy J Endocrinology. 2024; 165(4).

PMID: 38366552 PMC: 10904107. DOI: 10.1210/endocr/bqae022.

New insights into the correlations between circulating tumor cells and target organ metastasis.

Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y Signal Transduct Target Ther. 2023; 8(1):465.

PMID: 38129401 PMC: 10739776. DOI: 10.1038/s41392-023-01725-9.

References

Karantanos T, Corn P, Thompson T . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-11. PMC: 3908870. DOI: 10.1038/onc.2013.206. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M . A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2011; 106(3):508-16. PMC: 3273340. DOI: 10.1038/bjc.2011.545. View

Phillips K, Kolatkar A, Rees K, Rigg R, Marrinucci D, Luttgen M . Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient. Front Oncol. 2012; 2:96. PMC: 3414893. DOI: 10.3389/fonc.2012.00096. View

Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

Lohr J, Adalsteinsson V, Cibulskis K, Choudhury A, Rosenberg M, Cruz-Gordillo P . Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32(5):479-84. PMC: 4034575. DOI: 10.1038/nbt.2892. View

Zhang J, Fujimoto J, Zhang J, Wedge D, Song X, Zhang J . Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256-9. PMC: 4354858. DOI: 10.1126/science.1256930. View

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S . Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6(254):254ra125. PMC: 4422178. DOI: 10.1126/scitranslmed.3009448. View

10.

Crockford A, Jamal-Hanjani M, Hicks J, Swanton C . Implications of intratumour heterogeneity for treatment stratification. J Pathol. 2013; 232(2):264-73. DOI: 10.1002/path.4270. View

11.

Parkinson D, Dracopoli N, Petty B, Compton C, Cristofanilli M, Deisseroth A . Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMC: 3478228. DOI: 10.1186/1479-5876-10-138. View

12.

Miller M, Doyle G, Terstappen L . Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2009; 2010:617421. PMC: 2793426. DOI: 10.1155/2010/617421. View

13.

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

14.

Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo J . Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol. 2010; 331(1):57-65. DOI: 10.1016/j.mce.2010.08.008. View

15.

Hiley C, de Bruin E, McGranahan N, Swanton C . Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 2014; 15(8):453. PMC: 4281956. DOI: 10.1186/s13059-014-0453-8. View

16.

Phin S, Moore M, Cotter P . Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 2013; 3:240. PMC: 3775430. DOI: 10.3389/fonc.2013.00240. View

17.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

18.

Mateo J, Gerlinger M, Nava Rodrigues D, de Bono J . The promise of circulating tumor cell analysis in cancer management. Genome Biol. 2014; 15(8):448. PMC: 4281949. DOI: 10.1186/s13059-014-0448-5. View

19.

Kang Y, Pantel K . Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013; 23(5):573-81. PMC: 3667710. DOI: 10.1016/j.ccr.2013.04.017. View

20.

Meacham C, Morrison S . Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-37. PMC: 4521623. DOI: 10.1038/nature12624. View